Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial.

被引：1
|
作者：
Ribi, K.
Aldridge, J.
Phillips, K.
Sun, Z.
Thompson, A. M.
Harvey, V. J.
Thuerlimann, B.
Cardoso, F.
Coates, A. S.
Bernhard, J.
机构：
[1] Int Beast Canc Study Grp, Bern, Switzerland
[2] Dana Farber Canc Inst, Int Beast Canc Study Grp Stat Ctr, Boston, MA 02115 USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Dundee, Dundee, Scotland
[5] Auckland Hosp, Auckland, New Zealand
[6] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland
[7] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
    Zaman, K.
    Thuerlimann, B.
    Huober, J.
    Schoenenberger, A.
    Pagani, O.
    Luethi, J.
    Simcock, M.
    Giobbie-Hurder, A.
    Berthod, G.
    Genton, C.
    Brauchli, P.
    Aebi, S.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1474 - +
  • [22] Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
    Metzger Filho, Otto
    Giobbie-Hurder, Anita
    Mallon, Elizabeth
    Gusterson, Barry
    Viale, Giuseppe
    Winer, Eric P.
    Thuerlimann, Beat
    Gelber, Richard D.
    Colleoni, Marco
    Ejlertsen, Bent
    Debled, Marc
    Price, Karen N.
    Regan, Meredith M.
    Coates, Alan S.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2772 - U85
  • [23] Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
    Koeberle, Dieter
    Thuerlimann, Beat
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 105 (Suppl 1) : 55 - 66
  • [24] DESIGN AND EVOLUTION OF BIG 1-98: A RANDOMIZED, DOUBLE-BLIND, PHASE-III STUDY COMPARING LETROZOLE AND TAMOXIFEN AS ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE, EARLY BREAST CANCER - BIG 1-98 COLLABORATIVE AND INTERNATIONAL BREAST CANCER STUDY GROUPS
    Giobbie-Hurder, A. E.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 80 - 80
  • [25] Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis
    Thuerlimann, B.
    BREAST, 2009, 18 : S60 - S60
  • [26] ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
    Leyland-Jones, Brian
    Gray, Kathryn P.
    Abramovitz, Mark
    Bouzyk, Mark
    Young, Brandon
    Long, Bradley
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Biasi, Maria Olivia
    Thuerlimann, Beat
    Harvey, Vernon
    Neven, Patrick
    Arnould, Laurent
    Maibach, Rudolf
    Price, Karen N.
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    Pagani, Olivia
    Viale, Giuseppe
    Rae, James M.
    Regan, Meredith M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 543 - 555
  • [27] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
    Alkner, S.
    Jensen, M. -B.
    Rasmussen, B. B.
    Bendahl, P. -O.
    Ferno, M.
    Ryden, L.
    Mouridsen, H.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 481 - 490
  • [28] Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer:: The BIG 1-98 trial
    Crivellari, Diana
    Sun, Zhuoxin
    Coates, Alan S.
    Price, Karen N.
    Thuerlimann, Beat
    Mouridsen, Henning
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert J.
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Colleoni, Marco
    Lang, Istvan
    Del Mastro, Lucia
    Gladieff, Laurence
    Rabaglio, Manuela
    Smith, Ian E.
    Chirgwin, Jacquie H.
    Goldhirsch, Aron
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 1972 - 1979
  • [29] ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
    Brian Leyland-Jones
    Kathryn P. Gray
    Mark Abramovitz
    Mark Bouzyk
    Brandon Young
    Bradley Long
    Roswitha Kammler
    Patrizia Dell’Orto
    Maria Olivia Biasi
    Beat Thürlimann
    Vernon Harvey
    Patrick Neven
    Laurent Arnould
    Rudolf Maibach
    Karen N. Price
    Alan S. Coates
    Aron Goldhirsch
    Richard D. Gelber
    Olivia Pagani
    Giuseppe Viale
    James M. Rae
    Meredith M. Regan
    Breast Cancer Research and Treatment, 2015, 154 : 543 - 555
  • [30] Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
    S. Alkner
    M.-B. Jensen
    B. B. Rasmussen
    P.-O. Bendahl
    M. Fernö
    L. Rydén
    H. Mouridsen
    Breast Cancer Research and Treatment, 2017, 166 : 481 - 490
12345